|
|
|
|
Vol. 18, Issue 11, 4420-4437, November 2007
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||


*Institute of Molecular Medicine, College of Medicine, National Taiwan University, and Department of Medical Research, National Taiwan University Hospital, Taipei 100, Taiwan; and
Pulmonary-Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892-1434
Submitted February 20, 2007;
Revised August 21, 2007;
Accepted August 27, 2007
Monitoring Editor: Francis Barr
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
ARF-GEFs are linked to vesicular trafficking and cytoskeletal events underlying cell movement, secretion, and endocytosis (Jackson et al., 2000
; Shin and Nakayama, 2004
). ARF-GEFs that have homology with the Sec7 domain of yeast Sec7p have been identified by their ability to catalyze the exchange of GDP for GTP on ARF proteins in vitro (Chardin et al., 1996
; Jackson and Casanova, 2000
); the Sec7 domain is the only region of significant sequence similarity among ARF-GEFs, and the Sec7 domain alone is sufficient for guanine nucleotide-exchange activity (Chardin et al., 1996
; Beraud-Dufour et al., 1998
; Cherfils et al., 1998
; Mossessova et al., 1998
; Kremer et al., 2004
). To date, four members of cytohesin ARF-GEFs that are >77% identical have been identified, including cytohesin-1, cytohesin-2/ARF nucleotide-binding-site opener (ARNO), cytohesin-3/general receptor for phosphoinositides 1, and cytohesin-4. This family is characterized by a molecular structure that consists of an N-terminal coiled-coil domain, a central Sec7 domain, followed by a pleckstrin homology (PH) domain and an adjacent carboxy-terminal polybasic c domain (Nagel et al., 1998a
; Santy et al., 1999
; Jackson and Casanova, 2000
; Ogasawara et al., 2000
; Dierks et al., 2001
). The coiled-coil domain of the cytohesin proteins mediates homodimerization and also participates in protein–protein interaction. PH domains of cytohesins bind the lipid second messengers phosphatidylinositol 3,4,5-trisphosphate (PIP3) or phosphatidylinositol bisphosphate in vitro. The cytohesins seem to be involved in ARF6-mediated membrane trafficking and cytoskeletal reorganization (Jackson et al., 2000
; Dierks et al., 2001
; Santy and Casanova, 2001
; Moss and Vaughan, 2002
). In cells stimulated with an appropriate agonist, cytohesins can translocate from cytosol to plasma membrane to activate ARF6 in a phosphoinositide 3-kinase (PI3K)-dependent manner that requires both the PH and Sec7 domains of the cytohesin (Hemmings, 1997
; Nagel et al., 1998b
; Venkateswarlu et al., 1998
; Venkateswarlu et al., 1999
; Cullen and Chardin, 2000
; Venkateswarlu, 2003
).
ARLs share 40–60% amino acid sequence identity with ARFs and are highly conserved throughout eukaryotic evolution (Burd et al., 2004
; Kahn et al., 2006
). The best-characterized ARL protein, ARL1 is localized to the trans-Golgi network (TGN) and regulates trafficking in the TGN-endosomal pathways (Lu et al., 2004
). ARL2 regulates the folding of
-tubulin (Bhamidipati et al., 2000
). ARL4A, ARL4C, and ARL4D, whose expression is differentiation dependent, developmentally regulated, and tissue specific, may function in the nucleus (Schurmann et al., 1994
; Jacobs et al., 1999
; Lin et al., 2000
, 2002
). Disruption of the ARL4A gene in mice can reduce sperm count and a role(s) for ARL4A in the early stages of spermatogenesis in adults is inferred (Schurmann et al., 2002
). ARL4D was identified as an open-reading frame in a genomic region containing the BRCA1 gene (Harshman et al., 1995
; Smith et al., 1995
) and was reported to interact with HP1 (Lin et al., 2002
). Nevertheless, until now, relatively little is known about the cellular functions of ARL4D. To obtain additional clues to its physiological role(s), we attempted to identify interacting proteins, which may be downstream effectors.
Here, we present evidence that the ARF6-GEF, ARNO, is an effector of ARL4D. ARL4D interacted with ARNO in a GTP-dependent manner and the interaction required the C-terminal PH and polybasic c domains of ARNO. Localization of ARL4D to the plasma membrane was GTP dependent but it was not altered in ARNO knockdown cells or those overexpressing ARNO(E156K). In addition, ARL4D induced translocation of ARNO to the plasma membrane, with activation of ARF6 and loss of actin stress fibers. Knockdown of ARNO suppressed the effect of activated ARL4D on actin remodeling. ARL4D-induced redistribution of ARNO to the plasma membrane was not dependent on PI3K activation. These findings demonstrate a key role for ARL4D in the recruitment of cytohesin-2/ARNO to the plasma membrane along with ARF6 activation and actin remodeling.
| MATERIALS AND METHODS |
|---|
|
|
|---|
-tubulin, ARNO (Sigma-Aldrich, St. Louis, MO), ARF6, Na+/K+ ATPase (Santa Cruz Biotechnology, Santa Cruz, CA), Akt, phospho-Akt (Ser473) (Cell Signaling Technology, Danvers, MA), and plasma membrane calcium pump pan ATPase (PMCA) (Abcam, Cambridge, MA). Horseradish peroxidase-conjugated sheep anti-rabbit or anti-mouse immunoglobulin (IgG) antibodies were from GE Healthcare (Little Chalfont, Buckinghamshire, United Kingdom). Alexa Fluor 594, 488, or 350-conjugated anti-rabbit and anti-mouse antibodies were purchased from Invitrogen (Carlsbad, CA).
Expression Plasmids
ARL4D and mutants (Lin et al., 2002
) were subcloned into the mammalian expression vector pSG5 (Stratagene, La Jolla, CA). For expression as fusion with the LexA DNA-binding domain (BD) in yeast, the cDNA fragments of ARL4D and other ARF/ARLs cloned into the pBTM116 plasmid were used as described previously (Lin et al., 2002
). ARNO and its deletion mutant cDNA sequences were amplified by polymerase chain reaction (PCR) by using ARNO/pACT2 plasmid as a template (obtained from yeast two-hybrid screen) and oligonucleotide primers incorporating restriction sites. To introduce site-specific mutations in ARNO, a two-step recombinant PCR procedure was used. To generate ARNOC7A, seven basic charge amino acids in the polybasic c domain were replaced with alanine (386RKKRISVKKKQEQP399
386AAAAISVAAAQEQP399), by using a 3' primer in which the basic residues were replaced by alanine codons (5' CTC GAG TCA GGG CTG CTC CTG TGC TGC TGC GAC TGA AAT TGC TGC TGC TGC CGC TGC CAG CAT CTC ATA 3'). These constructs were subcloned in pACT2 for yeast two-hybrid assay. For expression as GST-fusion protein in Escherichia coli and N-terminal FLAG-fusion protein in mammalian cells, ARNO was cloned into pGEX-4T (GE Healthcare) and pCMV-Tag2 (Stratagene) vectors, respectively. For production of recombinant His-tagged proteins, ARNO and ARNO(E156K) were subcloned into the bacterial expression vector pET15b (Novagen, Madison, WI). ARF6 and ARL4D were cloned into the expression vector pET43a (Novagen). pACYC177/ET3d/yNMT, which encodes yeast (Saccharomyces cerevisiae) N-myristoyltransferase (Lin et al., 2002
) was used to myristoylate ARF6 and ARL4D in Escherichia coli. Cytohesin-3 and cytohesin-4 cDNA were synthesized by PCR from a prostatic adenocarcinoma cDNA pool (Clontech, Mountain View, CA), respectively. The GGA3 cDNA was amplified from a HeLa cell cDNA pool. Cytohesin-1 cDNA was kindly provided by Dr. M. Vaughan (National Institutes of Health, Bethesda, MD). Plasmid expressing Akt-PH-green fluorescent protein (GFP), which contains AKT1 (a.a. 1-164) with the PH domain (a.a. 6-107), was obtained from Dr. Z.-F. Chang (National Taiwan University, Taipei, Taiwan). Sequences of all constructs were confirmed by double-stranded sequencing.
Yeast Two-Hybrid Screen and Interaction Assay
The yeast strain L40 was constructed with two readouts for an interaction of histidine auxotrophy and
-galactosidase expression with the use of the LexA DNA-binding domain and GAL4-activation domain system. Using a lithium acetate transformation protocol (Clontech), mouse embryonic day 7 pACT2 cDNA library (Clontech) was screened using ARL4D(Q80L) as bait. The yeast two-hybrid screen and interaction assay was performed essentially as described previously (Lin et al., 2000
, 2002
). For histidine auxotrophy and
-galactosidase expression, we screened 6 x 106 clones, and we obtained 73 clones that specifically interacted with ARL4D(Q80L).
Guanosine 5'-O-(3-thio)triphosphate (GTP
S) Binding Assay
Preparation and purification of recombinant proteins were carried out as described previously (Pacheco-Rodriguez et al., 1998
; Lin et al., 2000
) The GTP
S-binding assay was carried out in a rapid filtration system as described previously (Pacheco-Rodriguez et al., 1998
; Lin et al., 2000
; Ogasawara et al., 2000
) with minor modification. Briefly, 50 µl of the reaction buffer (20 mM Tris-HCl, pH 8.0, 50 mM NaCl, 1 mM EDTA, 1 mM NaN3, 250 mM sucrose, 2 mM MgCl2, and 2 mM dithiothreitol [DTT]) containing 1 µg (
1 µM) of ARF6 or ARL4D; 40 µg of bovine serum albumin; 10 µg of L-
-phosphatidyl-L-serine; 0.1 µg each of aprotinin, leupeptin, and soybean, and lima bean trypsin inhibitors; 0.5 mM 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride; ARNO or ARNO(E156K) (1 µg unless otherwise specified); and 4 µM [35S]GTP
S (
2 x 106 cpm) were incubated for the indicated time at 30°C. The exchange reaction was terminated by cooling the sample on ice and transferring to nitrocellulose filters followed by washing six times with 2 ml of ice-cold wash buffer (25 mM Tris-HCl, pH 8.0, 5 mM MgCl2, 100 mM NaCl, 1 mM DTT, and 1 mM EDTA). Scintillation fluid was added to the filters, and they were counted in an LS 5000 beta-counter (Beckman Coulter, Fullerton, CA) to quantify the amount of [35S]GTP
S-bound protein. Data are reported as means ± SD of values from triplicate assays in a representative experiment. All observations have been replicated at least twice with different preparations of recombinant proteins.
SDS-Polyacrylamide Gel Electrophoresis (PAGE) and Immunoblotting Analysis
SDS-PAGE was performed according to the method of Laemmli (1970)
. Protein was visualized by Coomassie Brilliant Blue stain. For immunoblotting analysis, proteins were separated on SDS gel and electrotransferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA). Blocking and antibody dilutions were made in 5% low-fat dry milk in Tris-buffered saline (TBS) containing 0.1% Tween 20. Washing steps were in TBS containing 0.1% Tween 20. Membranes were blocked overnight at 4°C; primary and secondary antibodies were each incubated for 1 h at room temperature. Blots were developed using secondary antibodies coupled to horseradish peroxidase (GE Healthcare), and the immunoreactive bands were detected using the ECL system (GE Healthcare) after exposure to x-ray film. In peptide competition experiments,
30 µg of cell was loaded for each lane. The diluted primary antibody solution was preincubated overnight with equal amounts of immunogen (immunized peptide dissolved in dimethyl sulfoxide [DMSO]) or a control peptide.
Cell Culture and Transfection
COS-7 and human embryonic kidney (HEK) 293T cells were maintained in DMEM (Hyclone Laboratories, Logan, UT), supplemented with 10% fetal bovine serum (FBS) (Hyclone Laboratories), 100 U/ml penicillin, and 100 µg/ml streptomycin (Invitrogen) in a humidified incubator with 5% CO2 at 37°C. Transient transfections were performed using the Lipofectin reagent (Invitrogen) according to the manufacturer's protocol or calcium phosphate method. Cells were harvested 24–48 h later for analysis.
Glutathione S-Transferase (GST)-Fusion Protein Pull-Down Assay
GST pull-down analysis was performed essentially as described previously (Lin et al., 2002
). In brief, 293T cells transfected with ARL4D or mutants were lysed in radioimmunoprecipitation assay (RIPA) buffer containing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 µg/ml N
-
-tosyl-L-lysine chlorometyl ketone, 1 mg/ml benzamidine, and 1 µg/ml each pepstatin A, aprotinin, antipain, and leupeptin. The lysates were incubated with 10 µg of GST or GST-ARNO coupled to glutathione beads for 3 h at 4°C. The beads were then washed three times with the RIPA buffer, and the bound protein was analyzed by Western blot.
Coimmunoprecipitation
293T or COS-7 cells were cotransfected with ARL4D and FLAG-ARNO constructs by the calcium-phosphate method. After 48 h, cells were treated with 2 mM dithiobis succinimidylpropionate (DSP; Pierce Chemical, Rockford, IL), a thiol-cleavable cross-linker, to stabilize the protein complex, and lysed in NP-40 lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 1% NP-40). Lysates were cleared by centrifugation at 13,000 x g for 10 min at 4°C, incubated with M2 anti-FLAG affinity gel (Sigma-Aldrich) for 2 h at 4°C, and then washed three times in NP-40 lysis buffer and once in RIPA buffer. The coimmunoprecipitated proteins were analyzed by Western blot.
Immunofluorescence Microscopy
Cells were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) for 15 min and permeabilized with 0.01% Triton X-100 and 0.05% SDS in PBS for 5 min, and blocked with blocking buffer (0.1% saponin, 0.2% bovine serum albumin [BSA] in PBS) for an additional 30 min. Cells were incubated with primary antibodies in blocking solution for 1 h. After extensive washing with PBS, cells were incubated with the Alexa Fluor-conjugated secondary antibodies in blocking solution for 1 h and mounted in 90% glycerol in PBS containing 1 mg/ml
-phenylenediamine. For competition experiments, diluted primary antibody was preincubated overnight with equal amounts of immunogen (immunized peptide dissolved in DMSO) or a control peptide.
The plasma membrane localization of ARNO was determined as described previously (Ueda et al., 2007
). The ARNO membrane localization was evaluated by the fluorescence intensity profile of a typical line scan. The ratios of the average of two fluorescence signals of the plasma membrane to the average signal of the cytosol were measured using Axiovision 4.6 software (Carl Zeiss, Thornwood, NY). In the present study, we defined plasma membrane translocation as a ratio of >1.0. At least 50 different cells were analyzed for each condition. Results are the means ± SD of three independent experiments.
The quantification of F-actin fluorescence was performed as described previously (Poupel et al., 2000
; Yamashiro et al., 2001
). F-actin was stained with Alexa Fluor 594-conjugated phalloidin (Invitrogen). Mock-transfected, ARL4D, ARNO, or ARF6 mutant-expression cells were double labeled with the antibody and fluorescent phalloidin. Phalloidin-stained images were taken under the same conditions, and any images showing intensity saturation were excluded from analysis. The area around each cell was delineated, and the mean fluorescence intensity was measured in pixels. Background fluorescence was obtained from a cell-free field of each image and subtracted. Cells expressing exogenous proteins were randomly selected, and mean fluorescent intensities (to compensate for differences in cell size) of phalloidin staining were quantified using the Axiovision 4.6 software (Carl Zeiss). More than 50 cells were examined in each group, and two independent experiments were performed. The results were presented as the mean of the fluorescence intensity for each group of cells ± SD.
For stimulation with EGF, cells were serum starved for 14 h, and 100 ng/ml EGF (Upstate Biotechnology, Lake Placid, NY) was added for 10 min at 37°C. To inhibit PI3K-Akt activation, serum-starved cells were pretreated with 100 nM wortmannin or 1 µM LY294002 (Calbiochem, San Diego, CA) for 1 h, and then they were incubated with EGF in the continuous presence of wortmannin and LY294002. The phosphorylation level of Akt (Ser473) was used to confirm the inhibition of PI3K-Akt activation in each experiment. The staining was examined with a Zeiss Axioplan 2 fluorescence microscope (Carl Zeiss) with a 40x/1.3 numerical aperture (NA) oil objective lens. The images were acquired with a charge-coupled device (CCD) camera (AxioCam HRm; Carl Zeiss) operated by the Axiovision imaging software (Carl Zeiss). Some slides were optically sectioned, and the out-of-focus signals were removed using the ApoTome system (Carl Zeiss). The Apotome system provides an optical section slice view reconstructed from fluorescent samples, by using a series of "grid projection" acquisitions to reject signals belonging to regions of the sample that were outside the best focus position of the microscope. For confocal microscopy, cells were viewed on a Nikon C1 confocal microscope or LSM 510 META laser confocal microscope (Carl Zeiss) with 60x/1.4 NA oil objective lens and 488- or 543-nm lasers. Pinholes were set to scan layers <1 µm, at a resolution of 1024 x 1024 pixels. Both projection view and optical sections were processed digitally using CLSM5 Zeiss Browse Image software. Figures were assembled and labeled using Adobe Photoshop 7.0 (Adobe Systems, Mountain View, CA).
Small Interference RNA (siRNA)
Twenty one-nucleotide (nt) RNA duplexes were purchased from Dharmacon RNA Technologies (Lafayette, CO) for targeting ARL4D or from Ambion (Austin, TX) for targeting ARNO. The sequences of designed siRNAs are as follows (only sense sequences are shown): ARL4D siRNA, 5'-GGGAACCACUUGACUGAGAUU-3'; and ARNO siRNA, 5'-GAUGGCAAUGGGCAGGAAGtt-3'. Control siRNA (nontargeting siRNA pool) were purchased from Dharmacon RNA Technologies. Sixty percent confluent COS-7 or HeLa cells were transfected with siRNA at 100 nM concentration by using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's protocol. Cells were harvested after 48 h for immunoblotting and immunofluorescence assays.
Subcellular Fractionation
Subcellular fractionation was performed according to a method described previously (Fournier et al., 2005
), with a slight modification. HeLa cells were washed with PBS, resuspended in homogenization buffer (0.25 M sucrose, 1 mM EDTA, and 20 mM HEPES-KOH, pH 7.4) and incubated on ice for 15 min before disruption of cells by passing through 26-gauge needle 35 times until
70% of the cells were broken. All processing steps were performed at 4°C. After low-speed centrifugation (800 x g; 6 min) to isolate nuclei and unbroken cells, the postnuclear supernatant (PNS) was then centrifuged at 100,000 x g for 1 h to separate into crude cytosolic and membrane fractions. The membrane pellet and 10% PNS were resuspended in the cytosol volume of homogenization buffer, precipitated with trichloroacetic acid. The sedimented materials were resuspended in SDS sample buffer to the same volume, and an equal volume of different fraction was subjected to SDS-PAGE and Western blot analysis using various antibodies.
For ARNO translocation assay, transfected COS-7 cells (
1 x 106 cells) were harvested, washed with PBS, and treated with 1 mM DSP, and then the cytosol and membrane fractions of COS-7 cells were prepared using a CNM compartment protein extraction kit (BioChain Institute, Hayward, CA) according to the manufacturer's instructions.
Pull-Down Assay for ARF6-GTP
The activation levels of expressed ARF6 were assayed as described previously (Santy and Casanova, 2001
). COS-7 cells grown in 10-cm dishes were cotransfected with the indicated constructs and lysed in 1 ml of ice-cold lysis buffer (50 mM Tris-HCl, pH 7.5; 100 mM NaCl; 2 mM MgCl2; 0.1% SDS; 0.5% sodium deoxycholate; 1% Triton X-100; 10% glycerol, 50 µg/ml N
-
-tosyl-L-lysine chlorometyl ketone, 1 mg/ml benzamidine; and 1 µg/ml each pepstatin A, aprotinin, antipain, and leupeptin). Cell extracts were incubated with 20 µg of glutathione Sepharose-bound GST-GGA3 (a.a. 1-316) for 1 h at 4°C. The beads were then washed three times with 50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 2 mM MgCl2, 1% NP-40, and 10% glycerol. Bound proteins were analyzed by immunoblotting using ARF6 or myc antibodies. Immunoblots were scanned, and the GTP-bound ARF6 precipitated with GST-GGA3 was normalized to total ARF levels in the lysates to compare ARF6-GTP levels in cells transfected with the indicated constructs.
Migration Assays
Haptotactic migration assay were performed using a modified Boyden chamber assay, essentially as described previously (Palacios et al., 2001
). The lower surface of Transwell polycarbonate membranes (6.5 mm diameter, 8-µm pore size; Corning Life Sciences, Acton, MA) were coated with fibronectin (10 µg/ml in DMEM) overnight at 4°C. The membrane was washed in PBS to remove excess ligand, and the lower chamber was filled with 600 µl of migration medium (DMEM with 1% BSA or 10% FBS). Cells were serum starved for 16 h, and then 105 cells were suspended in 0.1 ml of DMEM containing 1% BSA were added to the upper chamber and allowed to migrate to the lower side for 6 h. Nonmigratory cells were removed using a cotton swab, whereas migratory cells were fixed with 4% formaldehyde, stained with 1% crystal violet and count by phase-contrast microscopy by using a microscope (Eclipse TS-100; Nikon, Tokyo, Japan) equipped with a digital camera (DS-5M; Nikon). Migratory cells in five fields per well (Nikon Plan Fluor 10 x 0.30 objective) were counted for two individual wells per condition.
For wound-healing migration assays, cells were seeded on six-well plates at a density of 7 x 105 cells/well in culture medium. Thirty hours after seeding, confluent cells were scratched with a fine pipette tip, washed with PBS, and time-lapse microscopy was performed using a microscope (Axiovert 200M; Carl Zeiss) equipped with a temperature and CO2 controller. Cell movement was recorded at 20-min intervals over 18 h with a CCD video camera (CoolSNAP HO; Roper Scientific, Trenton, NJ) operated by MetaMorph 7.0 image analysis software (Molecular Devices, Sunnyvale, CA). Quantitation of cellular migration was performed as described previously (Santy and Casanova, 2001
). The area covered by the monolayer (decreased wound area) was traced and measured using MetaMorph 7.0 software.
| RESULTS |
|---|
|
|
|---|
C, the GTP-binding-defective mutant ARL4D(T35N) or ARL4A(T34N). These results indicated that the interactions were specific, nucleotide dependent, and involved the C terminus of ARL4D.
|
C. GST alone failed to pull down ARL4D constructs. Next, we used coimmunoprecipitation experiments to demonstrate that ARL4D interacts with ARNO. Proteins immunoprecipitated from lysates of 293T cells coexpressing ARL4D or mutants and FLAG-ARNO with anti-FLAG M2 affinity gel were immunoblotted with antibodies against ARL4D or FLAG. As shown in Figure 1D, ARL4DWT, ARL4D(Q80L), or ARL4D(G2A), but not ARL4D(T35N) or ARL4D
C, was coimmunoprecipitated with FLAG-ARNO. Thus, we demonstrated interactions of recombinant ARNO and ARL4D that were nucleotide dependent and involved in the C-terminal NLS domain by using proteins synthesized in bacteria or in 293T cells.
The PH Domain and the Polybasic C Domain of ARNO Are Both Necessary and Sufficient for Interaction with ARL4D
All ARNO clones isolated from the yeast two-hybrid screening contained an intact PH domain and partial Sec7 domain, suggesting that the C-terminal PH domain of ARNO may be involved in the interaction with ARL4D. To identify the specific domains of ARNO responsible for this interaction, a series of ARNO-deletion mutants was generated (Figure 2A) and tested for the ability to interact with ARL4D in yeast two-hybrid assays (Figure 2B). We found that the C-terminal 140 amino acids (ARNOCT) alone were sufficient for the interaction; the N-terminal coiled-coil and central Sec7 domains were not required. ARL4D interaction with the ARNO PH domain (ARNOPH) was much weaker than that of the C-terminal PH domain and polybasic c domain (ARNOCT) (Figure 2B), indicating that, besides the PH domain, the C-terminal polybasic c domain is also important. The C-terminal polybasic stretch of cytohesin-1 and ARNO was reported to be important for its collaboration with the PH domain in membrane recruitment and phospholipids PIP3 binding (Nagel et al., 1998a
; Macia et al., 2000
; Dierks et al., 2001
). To determine whether the basic charge amino acids in the C-terminal polybasic stretch is important for the interaction between ARL4D and ARNO, we used site-directed mutagenesis to generate an ARNO mutant, ARNOC7A, in which the seven basic residues were replaced with alanine. Interestingly, ARNOC7A, like ARNO, showed similar interaction ability for ARL4D (Figure 2B). This result indicates that the C-terminal basic amino acids are not involved in the interaction between ARL4D and ARNO. These constructs were expressed in relatively equal amounts in the transformed yeast (unpublished data).
|
CT (Figure 2C). Thus, our results demonstrate that the PH domain and polybasic c domain of ARNO are necessary and sufficient for interaction with ARL4D.
ARNO Does Not Catalyze Nucleotide Exchange on ARL4D
ARNO has previously been shown to catalyze guanine nucleotide exchange on ARF6 in vitro (Frank et al., 1998a
). To determine whether ARL4D is a substrate of ARNO, we measured the ability of ARNO to catalyze the binding of GTP
S on ARF6 and ARL4D. Consistent with the previous observation (Frank et al., 1998a
), ARF6 undergoes spontaneous nucleotide exchange even in the absence of ARNO and addition of ARNO results in a stimulation of GTP
S binding (Supplemental Figure S1A and S1B). However, no stimulation of GTP
S binding was observed when using ARL4D as substrate. Our data indicated that ARNO could not catalyze nucleotide exchange on ARL4D in the GTP
S binding assay.
Localization of ARL4D at the Plasma Membrane Is GTP Dependent
Our previous studies showed that N-terminally enhanced green fluorescent protein (EGFP)-tagged ARL4D is located in nuclei and partially in nucleoli and can interact with importin-
through its C-terminal bipartite NLS (Lin et al., 2002
). However, ARL4D has a myristoylation site at its N terminus and a NLS in its C terminus; thus, epitope tags at either end might sterically hinder and change its conformation, localization, and function. To examine the physiological phenotype of ARL4D, we first used two unique peptides (peptide N corresponding to a.a. 2-18 and peptide B a.a. 139-155 of ARL4D) to generate peptide-specific antibodies (Supplemental Figure S2A). A Blast search using the peptide sequences of ARL4D-N and ARL4D-B did not reveal any homologous peptides. The antibody against peptide B was more sensitive in detecting purified recombinant human ARL4D in low nanogram amounts, whereas no reaction was detected with 100 ng of recombinant human ARL4A, ARF1, or ARF6 proteins (Supplemental Figure S2B). Using this antibody, endogenous ARL4D was detected in three cell lines (Supplemental Figure S2C). The detected
25-kDa band was similar in size to recombinant ARL4D protein expressed in HeLa cells.
To determine the subcellular localization of ARL4D, we first analyzed overexpression of ARL4D and its mutants in transiently transfected COS-7 cells by indirect immunofluorescence microscopy (Figure 3A). The stacked images were obtained by using a confocal microscope. The single plane images of transfected cells are shown in Supplemental Figure S3. Interestingly, ARL4D was detected at the plasma membrane, in addition to the nucleus and cytoplasm. Like ARL4D(WT), ARL4D(Q80L) was detected in the nucleus and diffusely throughout the cytoplasm but concentrated most intensely at the plasma membrane, where it associated with areas of membrane folding or ruffles along the periphery of the cell. Notably, cells transfected with ARL4D(Q80L) also demonstrated membranous protrusion structures from their dorsal surface, and ARL4D(Q80L) was also concentrated within these structures. Nuclear, perinuclear punctate, and diffuse cytoplasmic labeling, but much less plasma membrane-associated signals, were detected in cells expressing ARL4D(T35N). Our results indicated that subcellular localization of ARL4D was guanine nucleotide dependent. We further showed that ARL4D(G2A), containing Ala substituted for Gly at position 2, was diffusely distributed in the cytoplasm (Figure 3A), indicating that N-terminal myristoylation is important for association with the plasma membrane.
|
42-kDa band on immunoblots, which was only seen with nuclear fractions, was abolished by the addition of a specific ARL4D-B antigen (Figure 3, B and C). Whether the
42-kDa band is the source of the nuclear staining due to endogenous proteins needs to be further investigated. We also examined the subcellular localization of endogenous ARL4D in interphase HeLa cells. Endogenous ARL4D, like overexpression of ARL4D, was detected at the plasma membrane, in addition to the nucleus and cytoplasm (Figure 3D). PMCA was used as a control. The signals of ARL4D were abolished when the antibody was preincubated with the ARL4D-B peptide used for immunization, but not with DMSO or ARL4D-N peptide.
Both the PH Domain and Polybasic c Domain, but Not GEF Activity of ARNO, Are Required for ARL4D-Induced Recruitment of ARNO to the Plasma Membrane
The PH domain of ARNO is required for its membrane targeting or translocation (Venkateswarlu et al., 1998
). We examined whether ARL4D could affect the subcellular localization of ARNO in transiently transfected COS-7 cells. Figure 4A showed that FLAG-ARNO was detected as a diffuse signal throughout the cytoplasm and was not clearly observed at the periphery plasma membrane in COS-7 cells. Coexpression of FLAG-ARNO and ARL4D(WT) or its mutants reveals that part of FLAG-ARNO was colocalized with ARL4D(WT) or ARL4D(Q80L) at plasma membrane ruffles and dorsal membranous protrusions. This translocation of ARNO was not observed in cells coexpressing ARL4D(G2A) or ARL4D(T35N) (Figure 4B). We confirmed the effect of ARL4D(Q80L) on ARNO translocation to the membrane fraction by subcellular fractionation (Supplemental Figure S4). We also observed similar effects of ARL4D on ARNO in HeLa and Madin Darby canine kidney (MDCK) cells (unpublished data). The localization of ARL4D or its mutants was not altered when coexpressed with FLAG-ARNO (compare with Figures 3 and 4B). Quantitation of the ARNO fluorescence signal confirmed that ARL4D(WT) or ARL4D(Q80L) induced ARNO redistribution to the plasma membrane (Figure 4, C and D). Moreover, overexpression of ARF1(Q71L) or ARL1(Q71L) did not affect the distribution of FLAG-ARNO (unpublished data). Collectively, these data indicate that ARL4D can induce ARNO redistribution to the plasma membrane and this effect is GTP dependent.
|
CT or ARNOCT and/or ARL4D(Q80L). Similar to that of wild-type ARNO, the localization of ARNO
CT or ARNOCT is detected in the cytoplasm, and it did not seem to concentrate at the lateral margins (Supplemental Figure S5A and S5B). Although ARL4D(Q80L) could not induce redistribution of ARNO
CT to the plasma membrane, ARNOCT and ARNOC7A were translocated to ARL4D(Q80L)-enriched plasma membrane in a manner similar to full-length FLAG-ARNO (Supplemental Figure S5B and S5C). Moreover, ARL4D(Q80L) can only recruit less amounts of ARNOPH than full-length ARNO to the plasma membrane (Supplemental Figure S5D). Our data demonstrate that ARL4D mediates redistribution of ARNO through its C-terminal PH domain and polybasic c domain.
ARNO is a GEF for ARF1 and ARF6 (Chardin et al., 1996
; Frank et al., 1998a
); thus, we were interested to learn whether ARL4D-regulated translocalization of ARNO is dependent on ARNO GEF activity. To test this, we constructed a catalytically inactive GEF form of ARNO, ARNO(E156K). When expressed in COS-7 cells, ARNO(E156K) exhibited a distribution similar to that of wild-type ARNO (Supplemental Figure S6A). ARNO(E156K) was coprecipitated by ARL4D(Q80L) (Figure 2C), and, like the wild-type ARNO, ARNO(E156K) was also recruited to the ARL4D(Q80L)-enriched plasma membrane region (Supplemental Figure S6B). Moreover, coexpression of ARNO(E156K) or down-regulation of endogenous ARNO by siRNA in COS-7 cells did not affect the distribution of ARL4D(WT) (unpublished data). These data suggest that induced redistribution of ARNO by ARL4D does not require ARNO GEF activity.
ARL4D Promotes Activation of ARF6
Translocation of ARNO to the plasma membrane is a critical event for ARNO GEF activity and ARF6 activation. We examined whether ARL4D-induced ARNO membrane-targeting can promote the activation of ARF6. We showed in Figure 5A that cells cotransfected with ARF6 and ARL4D(Q80L) exhibited colocalization along plasma membrane ruffles and protrusions. Conversely, ARF6 showed little or no colocalization with ARL4D(T35N). We carried out a pull-down assay to detect ARF6 states by using a GST fusion construct containing the VPS27, Hrs, and STAM- and ARF-binding domains of GGA3 (Santy and Casanova, 2001
). ARF6(Q67L) bound to GST-GGA3 was used as a control (Figure 5B). In COS-7 cells, wild-type ARF6-myc was coexpressed with either hemagglutinin (HA)-ARNO, ARL4D(Q80L), or ARL4D(T35N). ARL4D(Q80L), but not ARL4D(T35N), stimulated ARF6 activation. Consistent with a previous report (Santy and Casanova, 2001
), ARF6 activation was stimulated by ARNO (Figure 5B). Moreover, cells coexpressed with HA-ARNO and ARL4D(Q80L) increased the GTP-bound form of endogenous ARF6 (Figure 5C). Together, these results indicate that ARL4D recruits ARNO to the plasma membrane and thus promotes activation of ARF6.
|
|
-tubulin, or ARF6. We further used siRNA knockdown to ask whether reduction of ARNO could block ARL4D(Q80L)-mediated actin remodeling. The localization of ARL4D(WT) or ARL4D(Q80L) in ARNO knockdown cells remained unchanged; however, ARL4D(Q80L)-induced stress fiber reduction was significantly decreased (Figure 6E; data not shown). In contrast, reduction of ARL4D had no affect on ARNO-mediated decrease in actin stress fibers (Figure 6F). It clearly demonstrated that ARNO is the direct downstream effector of ARL4D on the actin remodeling. Consistent with the result from ARNO GEF inactivation, an inactive form of ARF6 (T27N), blocked ARL4D(Q80L)-induced actin remodeling. ARL4D(T35N) did not block ARF6(Q67L)-mediated cytoskeletal rearrangements (Figure 6, B and C) or interfere with the ARNO-mediated reduction of actin stress fibers (Figure 6, B and C). These data demonstrate that ARL4D effects on actin remodeling lie upstream of ARNO and ARF6.
Requirement for ARL4D in Cell Migration
Expression of ARNO or activation of ARF6 stimulates MDCK cell migration (Palacios et al., 2001
; Santy and Casanova, 2001
), and suppression of ARF6 blocks invasive and migration activities of breast cancer cells (Hashimoto et al., 2004
). To investigate the potential role of ARL4D in cell migration, we assessed whether knockdown of the endogenous ARL4D would impair cell motility. We used a Transwell migration assay with control siRNA, ARL4D siRNA, and ARNO siRNA in HeLa cells. The cells were plated in the upper chamber containing filters that had been coated with fibronectin on the underside, and they were allowed to migrate for 6 h. As shown in Figure 7, B and C, HeLa cells transfected with either ARL4D siRNA or ARNO siRNA showed a significantly reduced motility compared with control siRNA. We also used a wound-healing assay to monitor cell migration and obtained similar results. Namely, knockdown of ARL4D or ARNO expression caused a delay in wound closure (Figure 7D). Quantification of the wound area covered by the migrating monolayer cell is shown in Figure 7E. Together, these results provide evidence that ARL4D play a physiological role in cell motility.
|
|
ARL4D Recruits Other Members of Cytohesin Family, but Not Akt PH Domain, to the Plasma Membrane
Because of highly structural conservation of the PH domain in the cytohesin family (Ogasawara et al., 2000
), we next examined whether ARL4D can induce redistribution of other cytohesins, including cytohesin-1, cytohesin-3, and cytohesin-4, to the plasma membrane. All FLAG-tagged cytohesins were diffusely localized throughout the cytoplasm (Supplemental Figure S7). When coexpressed with ARL4D(Q80L), the redistribution of FLAG-cytohesin-1, FLAG-cytohesin-3, and FLAG-cytohesin-4 to plasma membrane ruffles and protrusions was detected (Supplemental Figure S7). Together, these results illustrate that the effect of ARL4D on the subcellular localization of all members of the cytohesin family is similar.
Despite high primary sequence variability, PH domains retain a conserved three-dimensional organization consisting of seven-stranded
-sandwich structure, with one corner capped off by a C-terminal
-helix and another by three interstrand loops. However, different PH domains have different affinities to several kinds of phospholipids (Lemmon, 2004
; Balla, 2005
). There has been speculation about the key regulator(s) of their specificity (Lemmon, 2004
; Balla, 2005
; Varnai et al., 2005
), especially concerning the protein–protein interaction. Similar to the PH domain of ARNO, the PH domain of Akt showed growth-factor-stimulated and wortmannin-sensitive translocation from the cytosol to the plasma membrane (Gray et al., 1999
). Thus, we next examined whether ARL4D can induce translocation of Akt-PH-GFP to the plasma membrane. However, a yeast two-hybrid assay showed that ARL4D could not interact with Akt-PH (unpublished data). In control, Akt-PH-GFP is localized to the cytoplasm and the nucleus (Figure 8H, top). In EGF-stimulated cells with or without coexpressing ARL4D, we found that Akt-PH-GFP localized to the plasma membrane (Figure 8, H and I). However, unlike the effect on ARNO, ARL4D did not induce redistribution of Akt-PH-GFP to the plasma membrane in the presence of wortmannin (Figure 8, H and I). This suggests that the interaction between ARL4D and cytohesin family proteins does not extend to another PIP3 membrane-associated PH domain-containing protein, and it reflects a novel and specific relationship between ARL4D and cytohesin family proteins.
| DISCUSSION |
|---|
|
|
|---|
|
(Lin et al., 2002
signaling could stimulate interaction of ARL4D with Smad2 and subsequently recruit ARL4D to a Smad2/Smad4 complex. This observation indicates that ARL4D may play another role in the nucleus and/or nucleoli under specific signaling regulation.
Cytohesin-2/ARNO Is a Downstream Effector of ARL4D
It is generally accepted that GEFs bind preferentially to GDP-bound or nucleotide-free GTPase, and GAPs to GTP-bound GTPase. The binary protein complex of nucleotide-free GTPase and GEF is thought to be an enzymatic reaction intermediate (Cherfils et al., 1998
; Day et al., 1998
). It is well established that ARNO stimulates nucleotide exchange on both ARF1 and ARF6 (Chardin et al., 1996
; Frank et al., 1998a
) through the Sec7 domain, with its hydrophobic surface groove for interaction with the switch 1 and switch 2 regions of ARFs (Betz et al., 1998
; Goldberg, 1998
; Mossessova et al., 1998
; Pacheco-Rodriguez et al., 1999
). ARNO-Sec7 formed a stable complex with the nucleotide-free form of N
17ARF1 (Paris et al., 1997
; Beraud-Dufour et al., 1998
). Unlike the typical association of a GEF with its substrate, an association between ARL4D and ARNO was found with ARL4D is in a GTP-bound state. This observation contrasts sharply with findings for the association between GEF and its bona fide substrates. The binding site for ARL4D(Q80L) in ARNO lies in the C-terminal PH domain and polybasic c domain, but not the Sec7 domain, indicating that ARNO may serve as an ARL effector rather than an activator. Moreover, our data showed that ARNO is not a GEF for ARL4D. Consistent with this notion, we showed that ARNO and ARNO(E156K) were translocated to the plasma membrane when they were coexpressed with ARL4D(Q80L). In addition, the amount of ARNO localized at the plasma membrane was not altered in cells coexpressing the membrane localization-defective mutant, ARL4D(G2A), although ARL4D(G2A) interacted with ARNO. We suggest that ARL4D might directly serve as a determinant for ARNO targeting to the plasma membrane.
ARL4D Modulates Actin Remodeling via Regulating ARNO and ARF6 Activity
In cells overexpressing ARL4D or ARL4D(Q80L), we observed a paucity of actin stress fibers. The effects of ARL4D on the actin cytoskeleton depend on its localization and the guanine nucleotide-bound state. Mutants with decreased affinity for GTP (T35N) or unable to localize at the plasma membrane (lacking the myristorylation site [G2A]) are unable to modulate actin remodeling.
ARF6-GTP initiates cortical actin rearrangement at the cell periphery, accompanied by a depletion of stress fibers (D'Souza-Schorey et al., 1997
; Boshans et al., 2000
). Previous studies had indicated that ARNO might be the GEF for ARF6. Overexpression of ARNO lead to disassembly of actin stress fibers, remodeling of the cortical actin cytoskeleton in HeLa cells (Frank et al., 1998b
), and development of broad lamellipodia in MDCK cells with a dramatic increase in migratory behavior (Santy and Casanova, 2001
). Coexpression of ARF6(T27N) or ARNO(E156K), or depletion of ARNO content with siRNA, prevented ARL4D(Q80L)-induced actin disassembly, suggesting that the activation of ARF6 and ARNO are downstream effects of ARL4D. ARNO-induced actin reorganization did not differ significantly in cells with reduced ARL4D expression, further supporting the idea. However, the amounts of actin stress fibers in ARNO-depleted cells overexpressing ARL4D(Q80L) were not as high as those cells overexpressing ARL4D(T35N) or inactive ARNO. Perhaps the action of ARNO remaining in siRNA-treated cells or of the other similar cytohesin/ARNO proteins may account for only partial decrease of actin stress fibers.
The overexpression of ARNO or activation of ARF6 induced a migratory phenotype (Palacios et al., 2001
; Santy and Casanova, 2001